Related Experiment Video
Updated: Jun 9, 2025
10:11
Immunohistochemical Staining of B7-H1 PD-L1 on Paraffin-embedded Slides of Pancreatic Adenocarcinoma Tissue
Published on: January 3, 2013
23.1K
B7-H3 is widely expressed in soft tissue sarcomas
Meghan M Lynch1, Rusul Al-Marayaty2, Farres Obeidin3
1Department of Internal Medicine, Northwestern University, Chicago, IL, USA.
BMC Cancer
|October 31, 2024
Summary
B7-H3 protein is highly expressed in most soft tissue sarcoma (STS) subtypes, indicating its potential as a therapeutic target. Further clinical trials are necessary to confirm if targeting B7-H3 benefits sarcoma patients.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
Background:
- Soft tissue sarcoma (STS) is a rare and heterogeneous cancer, posing challenges for targeted therapy development.
- B7 homolog 3 protein (B7-H3) is an immune checkpoint molecule with limited expression in normal tissues but overexpressed in various cancers.
- B7-H3 is a promising target for cancer therapy, with ongoing clinical trials.
Purpose of the Study:
- To characterize the expression patterns of B7-H3 across different subtypes of soft tissue sarcoma.
- To evaluate B7-H3 as a potential therapeutic target in STS.
Main Methods:
- Retrospective analysis of 153 STS tumor specimens from 15 different subtypes.
- Immunohistochemistry (IHC) was used to assess B7-H3 expression and staining patterns in tumor cells and associated vasculature.
Main Results:
- B7-H3 was broadly expressed in 97% of STS samples, with 69.2% showing high expression levels.
- No significant association was found between B7-H3 expression and prior treatments, tumor size, grade, or patient age.
- B7-H3 was present in tumor vasculature in 94.7% of samples and showed no correlation with PD-L1 or PD-1 expression.
Conclusions:
- High B7-H3 positivity across diverse STS subtypes supports its feasibility as a therapeutic target.
- Further clinical trials are warranted to determine the efficacy of B7-H3 targeting in sarcoma treatment.
